OBJECTIVE: To assess the association between antiretroviral adherence and the development of class-specific antiretroviral medication resistance. DESIGN AND METHODS: Literature and conference abstract review of studies assessing the association between adherence to antiretroviral therapy and the development of antiretroviral medication resistance. RESULTS: Factors that determine class-specific adherence-resistance relationships include antiretroviral regimen potency, viral fitness or, more specifically, the interplay between the fold-change in resistance and fold-change in fitness caused by drug resistance mutations, and the genetic barrier to antiretroviral resistance. During multidrug therapy, differential drug exposure increases the likelihood of developing resistance. In addition, antiretroviral medications with higher potency and higher genetic barriers to resistance decrease the incidence of resistance for companion antiretroviral medications at all adherence levels. CONCLUSION: Knowledge of class-specific adherence-resistance relationships may help clinicians and patients tailor therapy to match individual patterns of adherence in order to minimize the development of resistance at failure. In addition, this information may guide the selection of optimal drug combinations and regimen sequences to improve the durability of antiretroviral therapy.
OBJECTIVE: To assess the association between antiretroviral adherence and the development of class-specific antiretroviral medication resistance. DESIGN AND METHODS: Literature and conference abstract review of studies assessing the association between adherence to antiretroviral therapy and the development of antiretroviral medication resistance. RESULTS: Factors that determine class-specific adherence-resistance relationships include antiretroviral regimen potency, viral fitness or, more specifically, the interplay between the fold-change in resistance and fold-change in fitness caused by drug resistance mutations, and the genetic barrier to antiretroviral resistance. During multidrug therapy, differential drug exposure increases the likelihood of developing resistance. In addition, antiretroviral medications with higher potency and higher genetic barriers to resistance decrease the incidence of resistance for companion antiretroviral medications at all adherence levels. CONCLUSION: Knowledge of class-specific adherence-resistance relationships may help clinicians and patients tailor therapy to match individual patterns of adherence in order to minimize the development of resistance at failure. In addition, this information may guide the selection of optimal drug combinations and regimen sequences to improve the durability of antiretroviral therapy.
Authors: P Richard Harrigan; Robert S Hogg; Winnie W Y Dong; Benita Yip; Brian Wynhoven; Justin Woodward; Chanson J Brumme; Zabrina L Brumme; Theresa Mo; Chris S Alexander; Julio S G Montaner Journal: J Infect Dis Date: 2004-12-22 Impact factor: 5.226
Authors: Edward M Gardner; William J Burman; Moises E Maravi; Arthur J Davidson Journal: J Acquir Immune Defic Syndr Date: 2005-11-01 Impact factor: 3.731
Authors: Joseph Eron; Patrick Yeni; Joseph Gathe; Vicente Estrada; Edwin DeJesus; Schlomo Staszewski; Philip Lackey; Christine Katlama; Benjamin Young; Linda Yau; Denise Sutherland-Phillips; Paul Wannamaker; Cindy Vavro; Lisa Patel; Jane Yeo; Mark Shaefer Journal: Lancet Date: 2006-08-05 Impact factor: 79.321
Authors: D R Bangsberg; F M Hecht; E D Charlebois; A R Zolopa; M Holodniy; L Sheiner; J D Bamberger; M A Chesney; A Moss Journal: AIDS Date: 2000-03-10 Impact factor: 4.177
Authors: Birgitte B Simen; Jan Fredrik Simons; Katherine Huppler Hullsiek; Richard M Novak; Rodger D Macarthur; John D Baxter; Chunli Huang; Christine Lubeski; Gregory S Turenchalk; Michael S Braverman; Brian Desany; Jonathan M Rothberg; Michael Egholm; Michael J Kozal Journal: J Infect Dis Date: 2009-03-01 Impact factor: 5.226
Authors: Lily W Y Tam; Celia K S Chui; Chanson J Brumme; David R Bangsberg; Julio S G Montaner; Robert S Hogg; P Richard Harrigan Journal: J Acquir Immune Defic Syndr Date: 2008-11-01 Impact factor: 3.731
Authors: David R Bangsberg; Edward P Acosta; Reena Gupta; David Guzman; Elise D Riley; P Richard Harrigan; Neil Parkin; Steven G Deeks Journal: AIDS Date: 2006-01-09 Impact factor: 4.177
Authors: James C M Brust; Alain H Litwin; Karina M Berg; Xuan Li; Moonseong Heo; Julia H Arnsten Journal: AIDS Res Hum Retroviruses Date: 2010-11-23 Impact factor: 2.205
Authors: Steven Belenko; Richard Dembo; Michael Copenhaver; Matthew Hiller; Holly Swan; Carmen Albizu Garcia; Daniel O'Connell; Carrie Oser; Frank Pearson; Jennifer Pankow Journal: AIDS Behav Date: 2016-01
Authors: Mary Morrow; Samantha MaWhinney; Ryan P Coyle; Stacey S Coleman; Edward M Gardner; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Peter L Anderson; Jose R Castillo-Mancilla Journal: J Infect Dis Date: 2019-07-19 Impact factor: 5.226
Authors: Jose R Castillo-Mancilla; Mary Morrow; Ryan P Coyle; Stacey S Coleman; Edward M Gardner; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Samantha Mawhinney; Peter L Anderson Journal: Clin Infect Dis Date: 2019-04-08 Impact factor: 9.079
Authors: Jose R Castillo-Mancilla; Todd T Brown; Kristine M Erlandson; Frank J Palella; Edward M Gardner; Bernard J C Macatangay; Elizabeth C Breen; Lisa P Jacobson; Peter L Anderson; Nikolas I Wada Journal: Clin Infect Dis Date: 2016-09-22 Impact factor: 9.079
Authors: M R O'Donnell; A Daftary; M Frick; Y Hirsch-Moverman; K R Amico; M Senthilingam; A Wolf; J Z Metcalfe; P Isaakidis; J L Davis; J R Zelnick; J C M Brust; N Naidu; M Garretson; D R Bangsberg; N Padayatchi; G Friedland Journal: Int J Tuberc Lung Dis Date: 2016-04 Impact factor: 2.373